{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:28Z","timestamp":1787721628452,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to observe and compare the visual and anatomical improvements over 24 months in patients with diabetic macular edema (DME) treated with intravitreal conbercept injection following five initial monthly doses, using either a Pro Re Nata (PRN) regimen or a Treat-and-Extend (T&amp;amp;E) regimen. The injection and visit frequency were also compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively analyzed 119 patients with DME. Sixty patients received the 5+PRN regimen, while the other 59 patients were treated with the 5+T&amp;amp;E regimen. Baseline and post-treatment parameters, including best-corrected visual acuity (BCVA), central foveal thickness (CFT), microaneurysm count (MA count), retinal vein diameter, deep capillary plexus vessel density (DCP-VD), foveal avascular zone (FAZ) area, hard exudate (HE) area, and hemorrhage area, were recorded and compared between the two groups. The total number of intravitreal injections administered within 24 months was documented for both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant improvements in BCVA, CFT, and MA count were observed as early as 6 months after treatment in both groups, and these improvements were sustained through 24 months. Significant improvements in retinal vein diameter and DCP-VD became evident at 18 months post-treatment. Both the HE area and hemorrhage area showed significant improvements at 24 months after treatment. No statistically significant change in FAZ area was detected during the follow-up period. There were no significant differences in all therapeutic outcomes between the two groups. The mean number of injections within the 24-month follow-up was 14.02 \u00b1 2.05 in the 5+PRN group and 11.44 \u00b1 1.74 in the 5+T&amp;amp;E group. Meanwhile, the average number of follow-up visits was 24.89 \u00b1 1.67 in the 5+PRN group and 13.94 \u00b1 2.60 in the 5+T&amp;amp;E group. Both the injection frequency and follow-up visits were significantly lower in the 5+T&amp;amp;E group than in the 5+PRN group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Conbercept is safe and effective for the treatment of DME. Both the 5+PRN and 5+T&amp;amp;E regimens demonstrated significant improvements in visual acuity and retinal anatomical structure over the 24-month follow-up period. Over 24 months, the 5+T&amp;amp;E group had fewer mean injections and follow-up visits compared with the 5+PRN group, indicating that an individualized dosing strategy can reduce patient burden and healthcare costs while maintaining therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1875115","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:37Z","timestamp":1787719597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of conbercept pro re nata (PRN) versus treat-and-extend (T&amp;E) regimens following five initial monthly doses in diabetic macular edema: a 24-month retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengyao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Qilu Hospital, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Qingdao University, Affiliated Yantai Yuhuangding Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Jinan Huashi Ophthalmology Hospital","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Qilu Hospital, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Jinan Aier Eye Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Jinan Aier Eye Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jinan Second People\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Qilu Hospital, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000109276","article-title":"The status of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes: A survey from Beixinjing District of Shanghai City in China","volume":"222","author":"Wang","year":"2008","journal-title":"Ophthalmologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic macular edema pathophysiology: Vasogenic versus inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J Diabetes Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147585","article-title":"The role of intravitreal corticosteroids in the treatment of DME: Predictive OCT biomarkers","volume":"23","author":"Munk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108796","article-title":"Inflammation: The link between neural and vascular impairment in the diabetic retina and therapeutic implications","volume":"24","author":"Ramos","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/17590914221136365","article-title":"Multitarget activities of M\u00fcller glial cells and low-density lipoprotein receptor-related protein 1 in proliferative retinopathies","volume":"14","author":"Sanchez","year":"2022","journal-title":"ASN Neuro"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.781421","article-title":"Treat-and-extend vs. pro re nata regimen of ranibizumab for diabetic macular edema\u2014a two-year matched comparative study","volume":"8","author":"Lai","year":"2022","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1672839","article-title":"Comparative study on the efficacy of different aflibercept regimens in the treatment of macular edema secondary to branch retinal vein occlusion","volume":"12","author":"Du","year":"2025","journal-title":"Front Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318690","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","volume":"106","author":"Liu","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1218442","article-title":"Retinal vein changes in patients with high-risk proliferative diabetic retinopathy treated with conbercept and panretinal photocoagulation co-therapy: a cohort study","volume":"14","author":"Si","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"74\u201381","DOI":"10.1016\/j.ophtha.2016.09.021","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes","volume":"124","author":"Payne","year":"2017","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316176","article-title":"Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results","volume":"105","author":"Payne","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5\u2005mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Pr\u00fcnte","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02119-z","article-title":"Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial","volume":"39","author":"Garweg","year":"2022","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00033-1","article-title":"Patterns of diabetic macular edema with optical coherence tomography","volume":"127","author":"Otani","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1097\/IAE.0000000000000228","article-title":"Differential diagnosis of macular edema of different pathophysiologic origins by spectral domain optical coherence tomography","volume":"34","author":"Munk","year":"2014","journal-title":"Retina"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318285cc52","article-title":"Morphologic and functional evaluations during development, resolution, and relapse of uveitis-associated cystoid macular edema","volume":"33","author":"Munk","year":"2013","journal-title":"Retina-J Ret Vit Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"202\u20138","DOI":"10.1001\/jamaophthalmol.2017.6256","article-title":"Disorganization of inner retina and outer retinal morphology in diabetic macular edema","volume":"136","author":"Das","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2019.22687","article-title":"Defining cystoid macular degeneration in diabetic macular edema: An OCT-based single-center study","volume":"49","author":"Yal\u00e7\u0131n","year":"2019","journal-title":"Turkish J Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04722-8","article-title":"Characteristic distribution of microaneurysms and capillary dropouts in diabetic macular edema","volume":"258","author":"Takamura","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000357505","article-title":"Microaneurysm turnover in diabetic retinopathy assessed by automated RetmarkerDR image analysis--potential role as biomarker of response to ranibizumab treatment","volume":"231","author":"Leicht","year":"2014","journal-title":"Ophthalmologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog Retinal Eye Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14706","article-title":"Microaneurysm density in residual oedema after anti\u2010vascular endothelial growth factor therapy for diabetic macular oedema","volume":"99","author":"Yamada","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312258","article-title":"Morphological and topographical appearance of microaneurysms on optical coherence tomography angiography","volume":"103","author":"Schreur","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-3971-3","article-title":"Venous beading in two or more quadrants might not be a sensitive grading criterion for severe nonproliferative diabetic retinopathy","volume":"256","author":"Chen","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990022","article-title":"Pericyte loss in diabetic retinopathy: Mechanisms and consequences","volume":"20","author":"Beltramo","year":"2013","journal-title":"Curr Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.1995.tb00650.x","article-title":"Retinal vasodilation and hyperglycaemia in diabetic children and adolescents","volume":"73","author":"Falck","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.2560","article-title":"Changes in retinal vessel diameter and incidence and progression of diabetic retinopathy","volume":"130","author":"Klein","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14278","article-title":"Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12\u2010month prospective clinical trial","volume":"98","author":"Blindb\u00e6k","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.oret.2020.02.003","article-title":"Aflibercept reduces retinal hemorrhages and intravitreal microvascular abnormalities but not venous beading: Secondary analysis of the CLARITY study","volume":"4","author":"Pearce","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154332","article-title":"Retinal microvascular signs in pre- and early-stage diabetic retinopathy detected using wide-field swept-source optical coherence tomographic angiography","volume":"11","author":"Xu","year":"2022","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.008","article-title":"Visual acuity is correlated with the area of the foveal avascular zone in diabetic retinopathy and retinal vein occlusion","volume":"123","author":"Balaratnasingam","year":"2016","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ophtha.2019.06.016","article-title":"OCT angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: A prospective study","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11103","article-title":"The effects of macular ischemia on visual acuity in diabetic retinopathy","volume":"54","author":"Sim","year":"2013","journal-title":"Invest Ophth Vis Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ajo.2020.06.009","article-title":"Macular and peripapillary optical coherence tomography angiography metrics predict progression in diabetic retinopathy: A sub-analysis of TIME-2b study data","volume":"219","author":"Custo Greig","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.10.003522","article-title":"Three-dimensional structural and angiographic evaluation of foveal ischemia in diabetic retinopathy: method and validation","volume":"10","author":"Wang","year":"2019","journal-title":"BioMed Opt Express"},{"key":"B39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40942-017-0074-y","article-title":"Visualization of changes in the foveal avascular zone in both observed and treated diabetic macular edema using optical coherence tomography angiography","volume":"3","author":"Gill","year":"2017","journal-title":"Int J Retin Vitr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2016.09.019","article-title":"Acircularity index and axis ratio of the foveal avascular zone in diabetic eyes and healthy controls measured by optical coherence tomography angiography","volume":"139","author":"Krawitz","year":"2017","journal-title":"Vision Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.7.5.20","article-title":"Variability of foveal avascular zone metrics derived from optical coherence tomography angiography images","volume":"7","author":"Linderman","year":"2018","journal-title":"Transl Vis Sci Technol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1875115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:46:49Z","timestamp":1787719609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1875115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1875115"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1875115","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1875115"}}